|Toxiciy Grade:||4||City/State/Province:||Boston, Mass|
|Treatments:||Chemotherapy||Hospital:||Dana Farber/Partners Cancer Care Program|
Patients: This phase II trial involved 74 patients with epithelial ovarian cancer. Patients were separated into two groups - 58 women with platinum-resistant disease and 16 with platinum-sensitive disease. The overall median age was 57.
Treatment: Patients received intravenous irofluven. Irofluven is a derivative of a highly toxic molecule isolated from the Jack O'Lantern mushroom.
Toxicity: Toxicities included: grade 4 anorexia, nausea, thrombocytopenia and significant retinal toxicity.
Results: Overall median survival was not reported. There were only two documented responses (one for 3 months and one for 5 months). This study found that irofluven had limited antitumor activity (with these patients).
Support: The study was supported by a grant from MGI PHARMA Inc. This company manufactures and/or markets irofluven.
Correspondence: Dr. Michael Seiden